Pharmaceuticals

SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products BURLINGTON, Mass., Nov. 15, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGM...

2024-11-14 23:45 170

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug delivery, is excited to announce its official launch. The com...

2024-11-13 20:30 870

Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

MELBOURNE, Australia and BERLIN, Germany, Nov. 13, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement withBerlin -based Eckert & Ziegler SE (EZAG) for the use of EZAG's cyclotro...

2024-11-13 16:18 1085

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment

- CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment. - CBL-514 received both FDA Orphan Drug Designation and Fast Track designation for Dercum's disease treatment earlier this year. - CBL-514 Phase 2 study for Dercum's disease showed that it c...

2024-11-13 13:36 917

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III c...

2024-11-12 19:30 1172

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

* After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. * The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. * The safety and tolerability of G...

2024-11-12 19:00 1097

World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)

- Patent Covers Invention of Treatment Drug and Prophylactic Drug for Lowering Cardiac Disorder Markers in Dogs as Well as Their Manufacturing Methods - TOKYO, Nov. 12, 2024 /PRNewswire/ -- Scarecrow Incorporated, based in Tokyo's Shibuya Ward, is pleased to announce that it has acquired the worl...

2024-11-12 14:00 1065

Economist Impact's 4th edition Future of Health Asia to empower healthcare stakeholders by building strategies for a sustainable healthcare system, and igniting investment for an inclusive and healthier future

Members of the media are invited to register here . SINGAPORE, Nov. 11, 2024 /PRNewswire/ -- The 4th edition Future of Health A...

2024-11-11 20:56 1733

Diabetes Singapore and GSK Join Forces to Spotlight Increased Risk of Viral Infections for People with Diabetes

* Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day * 1 in 3 people will get shingles in their lifetime; People with diabetes are 38% more likely to contract shingles[1] * People with dia...

2024-11-11 20:47 1189

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

* Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0....

2024-11-11 19:36 1130

TB Alliance Joins Indonesia's High-Level Meeting on TB

Announces Strategy to Accelerate Efforts Toward Ending the TB Pandemic BALI, Indonesia, Nov. 11, 2024 /PRNewswire/ -- TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies...

2024-11-11 10:30 1212

Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024

SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune check...

2024-11-11 10:04 1259

Henlius and SVAX Forge Strategic Partnership in the MENAT Market

SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity ofSaudi Arabia's prominent family business group...

2024-11-09 00:35 4025

Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

* Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous(SQ) injection, demonstrated a half-life of 21 days, supporting once-monthly administration in patients with obesity * ...

2024-11-07 19:30 1462

Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders

Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 /PRNewswire/ -- Aditum Bio and Leads Biolabs today announced the formation of Oblenio Bio, which is being f...

2024-11-07 16:29 1560

Fosun Attends CIIE for the Seventh Time - Guo Guangchang: Confident that China's High-Level Openness is a Historical Opportunity

HONG KONG, Nov. 7, 2024 /PRNewswire/ -- On November 5, the 7th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center inShanghai. As a seven-time attendee of the CIIE, Fosun showcased the latest achievements in innovation and global operations at its Fosun...

2024-11-07 13:18 1738

Approx. USD 4.0 M Invested in Product Development for NTDs - GHIT's First Investment in the Development of Diagnostics for Trachoma

TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 578 million ( USD 4.0 million1) in four projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2  GH...

2024-11-07 10:00 1395

ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results...

2024-11-06 16:09 1322

ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that multiple studies o...

2024-11-06 15:56 1552

Leads Biolabs Receives Orphan Drug Designation from the US FDA for LBL-034, a Uniquely Designed, Highly Differentiated Anti-GPRC5D/CD3 Bispecific Antibody, for the Treatment of Multiple Myeloma

NANJING, China, Nov. 6, 2024 /PRNewswire/ -- On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Biolabs with glo...

2024-11-06 15:20 1191
12345 ... 187